Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
We have recently defined “immunogenic modulation,” a mechanism whereby malignant cells that survive anticancer therapy, due to sublethal delivery or development of treatment resistance, become nonetheless more sensitive to killing by cytotoxic T lymphocytes. This mechanism can be exploited to identi...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902115/ |